NewLink Genetics Appoints Chad A. Johnson to Board of Directors
AMES, Iowa,
|
"We welcome Mr. Johnson to our Board of Directors," said Charles J. Link, Jr, MD, Chairman and Chief Executive Officer. “His experience as a corporate officer, including governance, legal, and strategic business issues are important additions to NewLink Genetics.”
Mr. Johnson is currently Vice President, General Counsel for the
Prior to his position with
Mr. Johnson graduated from
“It’s an exciting time to be joining NewLink Genetics," said Mr. Johnson. “I look forward to working with the Board and the management team as the company advances toward multiple data disclosures from its clinical programs in cancer indications.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "guidance," "upcoming," "will," "plan," "anticipate," "approximate," "expect," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about NewLink Genetics' financial guidance for 2018; results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; NewLink Genetics' future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com
Media Contact:
Sharon Correia
VP,
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5937c758-39ab-41f3-96a3-f7ce581958c9
Source: NewLink Genetics Corporation